Biomarin Pharmaceutical Inc (LTS:0HNC)
$ 76.46 -0.06 (-0.08%) Market Cap: 14.69 Bil Enterprise Value: 14.74 Bil PE Ratio: 72.28 PB Ratio: 2.89 GF Score: 71/100

Biomarin Pharmaceutical Inc at Cowen HealthCare Conference Transcript

Mar 03, 2020 / 03:40PM GMT
Release Date Price: $91.33
Philip M. Nadeau
Cowen and Company, LLC, Research Division - MD & Senior Research Analyst

Good morning, and welcome once again to Cowen and Company's 40th Annual Health Care Conference. I'm Phil Nadeau, one of the biotech analyst here at Cowen. It's my pleasure to introduce the next presenting company, that's BioMarin. We have CEO, J.J. Bienaimé here with us today. He's going to give a corporate update with about 8 or 10 slides, and then he and I are going to have a Q&A session following. J.J.? Thank you.

Jean;Jacques BienaimÃ;BioMarin Pharmaceutical Inc.;Chairman;CEO

©,-&

Thank you, Phil. Good morning, everybody. Just want to highlight, as usual, that this presentation will contain forward-looking statements. For details about this, look at our 10-K, 10-Q and 8-K reports.

So I think most of you in the room are pretty familiar with the company. But in terms of overall mission of the company, we are entirely focused on rare and serious genetic disorders, most of them life-threatening.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot